Search for Terms or Answers
ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania.
Her aim was to highlight emerging therapies, preview trials expected
The content at ACR Orlando was vast. I looked at several posters/listened to many talks and heard from colleagues. Here is my list TOP 6 practice changing themes.
Obesity, in particular in psoriatic arthritis (PsA) was widely covered at #ACR26. This is from the recognition of the size of the problem.
TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942
TOGETHER-PsA at 52 weeks: ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone in PsA with overweight/obesity. n=271; open-label RCT. Joint, functional and metabolic outcomes improved. #2942 @Rheumnow #ACR26 #ACRBest https://t.co/zMNyrbAR5m
Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.